Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a universal cancer vaccine.
Originally published on 02/06/2016
BioNTech and its academic partners have published in the well-known publication Nature, describing the first clinically applicable and systemic mRNA cancer immunotherapy vaccine.
Based in Germany, BioNTech is one of the major players in the mRNA field along with US money-magnet Moderna and German CureVac, which has already raised €300M. BioNTech is now disclosing a major achievement: the first clinically relevant and systemic mRNA cancer vaccine in the world. Results published in Nature show that the therapy has a body-wide effect and elicits a strong immune response.
The research was performed in collaboration with several academic and clinical partners – TRON, Research Center for Immunotherapy (FZI), the University Medical Center at the Johannes Gutenberg University Mainz and the Heidelberg University Hospital.